Publication: Role of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment
Loading...
Files
Date
2022-08-01
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objective We aimed to evaluate whether baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters could be used as predictive biomarkers for survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line treatment. Materials and methods This retrospective study included 54 mCRPC patients, who underwent baseline Ga-68-PSMA PET/CT imaging within 1 month before starting first-line treatment. Pre-treatment prostate-specific antigen (PSA) levels and treatments were recorded. SUVmax, SUVmean, whole-body PSMA-derived tumor volume (wbPSMA-TV), and whole-body total lesion PSMA (wbTL-PSMA) were calculated for all patients. PSA response was defined as a decline of >= 50% from pre-treatment value at 12 weeks. Overall survival (OS) was measured from the start of the first-line treatment for mCRPC. Results Docetaxel and abiraterone/enzalutamide were administered to 32 and 22 patients in the first-line setting, respectively. wbPSMA-TV (rho = 0.582, p = 0.004) and wbTL-PSMA (rho = 0.564, p = 0.007) showed moderate positive correlations with PSA levels. Older age (p = 0.02), higher wbPSMA-TV (p = 0.007), higher PSA (p = 0.01), higher number of bone metastases (p = 0.02), and lack of PSA response (p = 0.03) were significantly associated with an increased risk of mortality. Multivariate analysis determined wbPSMA-TV (HR: 1.003, 95% CI 1.001-1.004, p = 0.001) and PSA response (HR: 2.241, 95% CI 1.189-4.222, p = 0.01) as independent predictors of OS. Conclusion The wbPSMA-TV may be a useful tool to reflect tumor burden and predict survival outcomes in patients with mCRPC.
Description
Keywords
Tıp, Dahili Tıp Bilimleri, Nükleer Tıp, Sağlık Bilimleri, Medicine, Internal Medicine Sciences, Nuclear medicine, Health Sciences, RADYOLOJİ, NÜKLEER TIP ve MEDİKAL GÖRÜNTÜLEME, Klinik Tıp, Klinik Tıp (MED), RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING, CLINICAL MEDICINE, Clinical Medicine (MED), Radyoloji ve Ultrason Teknolojisi, Radyoloji, Nükleer Tıp ve Görüntüleme, Radiological and Ultrasound Technology, Radiology, Nuclear Medicine and Imaging, Ga-PSMA PET/CT · Metastatic castration-resistant prostate cancer · Survival · Whole-body volumetric parameters
Citation
AKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S. , Sariyar N., Isik S., Arikan R., DEMİRCAN N. C. , BAŞOĞLU TÜYLÜ T., et al., "Role of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment", ANNALS OF NUCLEAR MEDICINE, 2022